Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract
Coleman RL et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(5):609-19. Abstract
Colombo N et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Eng J Med 2021;385(20):1856-67. Abstract
How JA et al. The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: An examination of toxicity and treatment efficacy in clinical practice. SGO 2021;Abstract 10775.
Liebold A et al. COVID-19 and gynecologic oncology: What have we learned? Curr Treat Options Oncol 2021;22(12):117. Abstract
Makker V et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437-48. Abstract
Oaknin A et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET–a phase I, single-arm study. J Immunother Cancer 2022;10(1):e003777. Abstract
O'Malley DM et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study. J Clin Oncol 2022;40(7):752-61. Abstract
Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39(36):4073-126. Abstract
Vergote I et al. Tisotumab vedotin (TV) + carboplatin (carbo) in first-line (1L) or + pembrolizumab (pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study. ESMO 2021;Abstract 723MO.